Rogalewicz B, Sierański T, Szczesio M, Olczak A, Gobis K, Orlewska C, Korona-Głowniak I, Korga-Plewko A, Iwan M, Michalczuk M, Kubik J, Adamczuk G, Korga M, Rutkowska N, Boruta T, Gas K, Sawicki M, Poleszak E, Maniukiewicz W, Świątkowski M, Czylkowska A
Institute of General and Ecological Chemistry, Faculty of Chemistry, Lodz University of Technology Żeromskiego 116 Lodz 90-924 Poland
Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Gdansk Gen. Hallera 107 Gdańsk 80-416 Poland.
RSC Adv. 2024 Nov 12;14(49):36295-36307. doi: 10.1039/d4ra06874b. eCollection 2024 Nov 11.
Two compounds, benzyl-2-(amino(pyrazin-2-yl)methylene)-1-methylhydrazine-1-carbodithioate (L) and its copper(ii) complex Cu(L) were synthesized and studied in terms of their physicochemical properties, including single crystal, spectroscopic and magnetic properties; simulations, including DFT calculations and pharmacokinetic profile analysis; and biological activity. The Cu(L) compound was found to exhibit good anticancer activity against A375, PANC-1, MKN-74, T-47D, HeLa, and NCI-H1563 cells, with the IC value against the HeLa cell line reaching 17.50 μM, significantly surpassing the activity of the organic ligand. Moreover, at the same time, the Cu(L) complex did not exhibit significant toxicity towards healthy cells. Mechanism of action studies revealed that its activity is connected with the oxidative stress and redox imbalance caused by the upregulation of genes encoding superoxide dismutase (SOD2) and catalase (CAT) antioxidant enzymes. The reported results further underscore the anticancer potential of pyrazine-based copper(ii) complexes.
合成了两种化合物,苄基-2-(氨基(吡嗪-2-基)亚甲基)-1-甲基肼-1-碳二硫代酸酯(L)及其铜(ii)配合物Cu(L),并对其物理化学性质进行了研究,包括单晶、光谱和磁性性质;模拟,包括密度泛函理论(DFT)计算和药代动力学特征分析;以及生物活性。发现Cu(L)化合物对A375、PANC-1、MKN-74、T-47D、HeLa和NCI-H1563细胞具有良好的抗癌活性,对HeLa细胞系的IC值达到17.50 μM,显著超过有机配体的活性。此外,同时Cu(L)配合物对健康细胞没有显著毒性。作用机制研究表明,其活性与超氧化物歧化酶(SOD2)和过氧化氢酶(CAT)抗氧化酶编码基因上调引起的氧化应激和氧化还原失衡有关。报道的结果进一步强调了吡嗪基铜(ii)配合物的抗癌潜力。